Study Comparing Chemotherapy Alone to Chemotherapy with Nivolumab or Nivolumab and BMS-986205 for Muscle Invasive Bladder Cancer
Sponsor: Bristol-Myers Squibb
ClinicalTrials ID:NCT03661320
This clinical trial is testing whether adding the drug nivolumab, or a combination of nivolumab and BMS-986205, to standard chemotherapy before surgery can improve treatment outcomes for adults with muscle-invasive bladder cancer. The study also looks at continuing these treatments after surgery.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The aim of this study is to see if adding the immunotherapy drug nivolumab, or a combination of nivolumab and BMS-986205, to the standard chemotherapy treatment of gemcitabine and cisplatin (GC) before surgery can help treat muscle-invasive bladder cancer more effectively. After surgery, participants will continue with either nivolumab alone or the combination of nivolumab and BMS-986205 to see if it helps prevent the cancer from returning.
Eligibility Criteria
Inclusion Criteria
- Must be eligible for a surgery called Radical Cystectomy, as determined by your cancer doctor or urologist, and agree to have this surgery after completing the initial treatment.
- Must be in good overall health, with a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
Exclusion Criteria
- Cannot have evidence of cancer spread to lymph nodes or other parts of the body.
- Cannot have had previous treatments like chemotherapy, radiation, or surgery for bladder cancer, except for a procedure called transurethral resection of bladder tumor (TURBT) or biopsies.
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.